NASDAQ · Financial Statements
Silence Therapeutics plc (SLN) Financial Statements
$9.80
NASDAQ: SLN
Market Cap $462.66M
Overview Financials Dividend
Silence Therapeutics plc most recently reported annual revenue of $1.0M, a net loss of $89.0M. Revenue declined at an average annual rate of 27.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $12.0M $18.0M $25.0M $43.0M $1.0M Operating Profit $-46.0M $-50.0M $-50.0M $-63.0M $-90.0M Net Profit $-39.0M $-41.0M $-43.0M $-45.0M $-89.0M EPS $-1.35 $-3.78 $-3.48 $-2.37 $-5.67 Op Margin -369.0% -281.9% -195.5% -146.4% -16056.0%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $96.0M $108.0M $95.0M $162.0M $131.0M Total Liabilities $88.0M $85.0M $77.0M $55.0M $69.0M Cash $74.0M $55.0M $54.0M $97.0M $11.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $9.0M $-57.0M $-39.0M $-54.0M $-62.0M Investing Cash Flow $10.0M $-21.0M $16.0M $-18.0M $-48.0M Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $62.0M $-33.0M $-1.0M $42.0M $-110.0M Free Cash Flow $7.0M $-58.0M $-39.0M $-54.0M $-62.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.19 EV / EBITDA -6.48 FCF Yield -9.15% Quick Ratio 7.42 Interest Coverage — Return 1Y 90.56% Return 3Y 4.20% Return 5Y -53.53%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .